H2020Индивидуална стипендия2022–2023

MONAGEL · anti-pseudoMOnas aeruginosa biofilm NAno-in-hydroGEL

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2022-01-01 → 2023-12-31
Финансиране от ЕС: 174 806 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Хидрогел с наночастици за инхалация се тества за едновременното освобождаване на антибиотици и вещества, които прекъсват комуникацията между бактериите Pseudomonas aeruginosa. Това помага за борбата с бактериалните биофилми, които предпазват микробите от стандартните лекарства.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

anti-pseudoMOnas aeruginosa biofilm NAno-in-hydroGEL

Pseudomonas aeruginosa (PA) is an ubiquitous and opportunistic gram-negative bacterium infecting particularly immunocompromised hosts. Moreover, PA has the capability to protect itself from current antibiotics by turning into a biofilm form. A new paradigm in research is that to fight biofilm infections, perturbating the biofilm might be a more effective strategy than using only classical antibiotics.Quorum sensing inhibition is such innovative strategy. Quorum sensing is the communication between bacteria regulating the biofilm. As the predictions of the WHO foresee the antibioresistance as one of the greatest danger of the 21st century, there is a dire need to create new strategies to fight bacterial infections. To this end the concept of the MONAGEL is to formulate an inhalable lipid nanoparticles based hydrogel to create a differential release kinetic between hydrophilic antibiotics and lipophilic quorum sensing inhibitors to fight PA biofilms.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Pseudomonas aeruginosa (PA) is ubiquitous gram-negative bacteria. PA is a serious threat and is considered as a critical priority for treatment development by various institutions such as the World Health Organization. PA can cause infections on various location such as eyes, lung, skin (wounds). Immunocompromised patients are especially at risk, as PA is also able to colonize domestic and hospital fixtures. To add insult to injury, the infection is hard to treat and the number of antibiotic resistant PA is on the rise. The major challenge opposed by PA is its biofilm. Biofilms are a structured bacterial community embedded in a matrix composed of exopolysaccharides, proteins, extracellular DNA, and lipids. PA present in the biofilm are a thousand times less sensitive to antibiotics than their planktonic form. The MONAGEL project propose to fight the PA in the biofilm by developing a hydrogel made of cross-linked lipid nanoparticles. The lipophilic core of the lipid nanoparticles will be used to encapsulate hydrophobic active ingredients, the aqueous cavities of the gel will be used to encapsulate hydrophilic ones. The hydrophobic and hydrophilic compartment will enable work with a broad variety of molecules such as fluorescent probes (which will permit a thorough characterisation of the gel) or active ingredients such as antibiotics and pathoblockers. The latter molecule will be efficient to design the gel towards fighting PA biofilm either by inhibiting quorum sensing (bacterial communication) or lectin interaction (key role in biofilm formation). Well thought work and contingency plans have been put in place to ensure the success of MONAGEL development. The innocuity of the system will be assessed on various cell lines, and the antibiofilm efficacy will be tested on in vitro models. In the end, the MONAGEL efficacy will be demonstrated on a co-culture model (epithelium + biofilm) as a proof-of-concept to serve as a selling point for further development.

Оригинален текст от CORDIS (на английски).

Участници

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH · BraunschweigКоординаторГермания